Clarity Pharmaceuticals (Clarity Pharmaceuticals) Days Payable : 0.00 (As of Dec. 2023)

View and export this data going back to 2022. Start your Free Trial

What is Clarity Pharmaceuticals Days Payable?

Clarity Pharmaceuticals's average Accounts Payable for the six months ended in Dec. 2023 was $2.29 Mil. Clarity Pharmaceuticals's Cost of Goods Sold for the six months ended in Dec. 2023 was $0.00 Mil.

The historical rank and industry rank for Clarity Pharmaceuticals's Days Payable or its related term are showing as below:

CLRPF's Days Payable is not ranked ^*
in the Biotechnology industry.
Industry Median: 149.7
* Ranked among companies with meaningful Days Payable only.

Clarity Pharmaceuticals's Days Payable stayed the same from Dec. 2022 (0.00) to Dec. 2023 (0.00).

Clarity Pharmaceuticals Days Payable Historical Data

The historical data trend for Clarity Pharmaceuticals's Days Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Clarity Pharmaceuticals Days Payable Chart

Clarity Pharmaceuticals Annual Data

Trend

Jun22

Jun23

Days Payable

Clarity Pharmaceuticals Semi-Annual Data
	Dec20	Dec21	Jun22	Dec22	Jun23	Dec23
Days Payable	Get a 7-Day Free Trial			-	-	-	-	-

Competitive Comparison of Clarity Pharmaceuticals's Days Payable

For the Biotechnology subindustry, Clarity Pharmaceuticals's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Clarity Pharmaceuticals's Days Payable Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Clarity Pharmaceuticals's Days Payable distribution charts can be found below:

* The bar in red indicates where Clarity Pharmaceuticals's Days Payable falls into.

Clarity Pharmaceuticals Days Payable Calculation

Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.

Clarity Pharmaceuticals's Days Payable for the fiscal year that ended in Jun. 2023 is calculated as

	Days Payable (A: Jun. 2023 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (A: Jun. 2022 )	+	Accounts Payable (A: Jun. 2023 ))	/	count )	/	Cost of Goods Sold (A: Jun. 2023 )	*	Days in Period
=	( (2.003	+	1.911)	/	2 )	/	0	*	365
=	1.957					/	0	*	365
=	N/A

Clarity Pharmaceuticals's Days Payable for the quarter that ended in Dec. 2023 is calculated as:

	Days Payable (Q: Dec. 2023 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (Q: Jun. 2023 )	+	Accounts Payable (Q: Dec. 2023 ))	/	count )	/	Cost of Goods Sold (Q: Dec. 2023 )	*	Days in Period
=	( (1.911	+	2.666)	/	2 )	/	0	*	365 / 2
=	2.2885					/	0	*	365 / 2
=	N/A

Clarity Pharmaceuticals Days Payable Related Terms

Thank you for viewing the detailed overview of Clarity Pharmaceuticals's Days Payable provided by GuruFocus.com. Please click on the following links to see related term pages.

Clarity Pharmaceuticals (Clarity Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Clarity Pharmaceuticals Ltd (OTCPK:CLRPF) » Definitions » Days Payable

Comparable Companies

Traded in Other Exchanges

CU6:Australia

Address

4 Cornwallis Street, National Innovation Centre, Eveleigh, Sydney, NSW, AUS, 2015

Website

https://www.claritypharmaceuticals.com

Clarity Pharmaceuticals Ltd is a clinical-stage radiopharmaceutical company developing next-generation theranostic (therapy and imaging) products, based on its platform SAR Technology. The SAR technology is ideally suited for use with copper isotopes, enabling superior imaging and therapeutic characteristics of radiopharmaceutical products and addressing the current manufacturing and logistical limitations in the growth of the radiopharmaceutical sector in oncology.